Human epidermal growth factor receptor 2 (HER2) amplification or overexpression is found in approximately 25% of diagnosed breast cancers and has been associated with an increased risk of developing distant metastases in younger women and a decrease in overall and progression-free survival (PFS) [3]. Here, ERBB2 is linked to breast cancer.